ORIG3N, Inc. announced that it has received $26.17493 million in funding from Haitong International Securities Company Limited, Investment Arm, Spectrum Health Ventures, LLC, KTB Ventures Inc., Laboratory Corporation of America Holdings, Hatteras Venture (2024)

LABCORP HOLDINGS INC.

Add to a list

To use this feature you must be a member

Log inSign up

Labcorp Holdings Inc.

Equities

LH

US5049221055

Market Closed - Nyse Other stock markets 04:00:02 2024-06-04 pm EDT			5-day change	1st Jan Change
196.7 ^USD	+0.86%		+0.25%	-13.47%

Jun. 04	Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM
Jun. 03	Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio	CI

September 08, 2020

On September 9, 2020, ORIG3N, Inc. closed the transaction. The company has received funding in its second tranche bringing the total funds raised in the transaction to $26,174,930. The transaction included participation from 11 investors.

Latest news about Labcorp Holdings Inc.

Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM	Jun. 04
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio	Jun. 03	CI
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261	May. 30	MT
Some of the biggest splits in Corporate America	May. 23	RE
Declaration of Voting Results by Laboratory Corporation of America Holdings	May. 16	CI
Declaration of Voting Results by Laboratory Corporation of America Holdings	May. 16	CI
Declaration of Voting Results by Laboratory Corporation of America Holding	May. 16	CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing	May. 16	MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating	May. 16	MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy	May. 15	CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal	May. 06	CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021.	Apr. 30	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244	Apr. 30	MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy	Apr. 29	MT
US FDA publishes final rule for laboratory developed tests	Apr. 29	RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B	Apr. 29	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255	Apr. 26	MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234	Apr. 26	MT
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating	Apr. 26	MT
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225	Apr. 25	MT
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating	Apr. 25	MT
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated	Apr. 25	MT
Transcript : Laboratory Corporation of America Holdings, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 Revenue $3.18B, vs. Street Est of $3.12B	Apr. 25	MT
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 EPS $3.68, vs. Street Est of $3.48	Apr. 25	MT

Chart Labcorp Holdings Inc.

Duration

Period

More charts

Company Profile

Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.

Sector

Related indices

More about the company

Income Statement Evolution

More financial data

Ratings for Labcorp Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

196.7USD

Average target price

238.5USD

Spread / Average Target

+21.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

	1st Jan change	Capi.
LABCORP HOLDINGS INC.	-13.47%	16.58B
HCA HEALTHCARE, INC.	+22.65%	86.96B
CVS HEALTH CORPORATION	-23.68%	75.65B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.63%	26.97B
	+5.20%	17.89B
QUEST DIAGNOSTICS INCORPORATED	+2.68%	15.73B
NATERA, INC.	+69.13%	13.01B
TENET HEALTHCARE CORPORATION	+74.99%	12.92B
FRESENIUS MEDICAL CARE AG	+3.90%	12.5B
UNIVERSAL HEALTH SERVICES, INC.	+21.12%	12.36B

Stock Market
Equities
LH Stock
News Labcorp Holdings Inc.
ORIG3N, Inc. announced that it has received $26.17493 million in funding from Haitong International Securities Company Limited, Investment Arm, Spectrum Health Ventures, LLC, KTB Ventures Inc., Laboratory Corporation of America Holdings, Hatteras Venture Partners, Alexandria Venture Investments, LLC

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019 Replicate our performance

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '13392');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });